Karyopharm announces xpovio® (selinexor) receives regulatory approval in israel for the treatment of patients with multiple myeloma and diffuse large b-cell lymphoma

Newton, mass., feb. 4, 2021 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq:kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner promedico ltd., a member of the neopharm group, has received a principal approval letter...
KPTI Ratings Summary
KPTI Quant Ranking